Arrowhead's plozasiran could reach $700M-plus in sales by 2032, meet major unmet need in dyslipidemia: GlobalData

With the ink still drying on Arrowhead Pharmaceuticals’ recent announcement of successful 48-week results in a phase 2 trial of its RNAi drug candidate plozasiran, analysts are already projecting much longer-term success for the drug.